<?xml version="1.0" encoding="UTF-8"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9">
  <url>
    <loc>https://www.biopharmawatch.com/news/SMMT/ivonescimab-monotherapy-significant-benefit-pembrolizumab</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-13T11:00:00.000Z</news:publication_date>
      <news:title>Ivonescimab Monotherapy Demonstrates a Statistically Significant &amp;amp; Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso’s HARMONi-2 Study Conducted in China</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/BETR/betterlife-pharma-us100-million-public-offering</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-11T23:45:00.000Z</news:publication_date>
      <news:title>BetterLife Pharma Inc. Announces Filing of Final Prospectus for US$100 Million Public Offering of Common Shares and Pre-Funded Warrants</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/MRBK/meridian-corporation-fiduciary-duties-investigation</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-11T22:48:00.000Z</news:publication_date>
      <news:title>SHAREHOLDER ALERT: Levi &amp; Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duties by Certain Officers and Directors of Meridian Corporation (NASDAQ: MRBK).</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/SRRK/fda-approval-isembyld-apitegromab-sma</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-11T22:25:00.000Z</news:publication_date>
      <news:title>Scholar Rock Announces FDA Approval of ISEMBYLD™ (apitegromab-mstn), the First and Only Muscle-Targeted Treatment for Children and Adults with Spinal Muscular Atrophy (SMA)</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/ENBI.X/entheon-adopts-semi-annual-reporting</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-11T22:18:00.000Z</news:publication_date>
      <news:title>Entheon Adopts Semi-Annual Reporting</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/CLLS/cellectis-conference-call-business-update-september-2026</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-11T20:30:00.000Z</news:publication_date>
      <news:title>Cellectis to Host Conference Call and Webcast on September 14 to Provide a Business Update</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/CMPS/strata-mental-health-solutions-training-grant-comp360</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-11T20:10:00.000Z</news:publication_date>
      <news:title>Strata Mental Health Solutions Awarded U.S. Healthcare Provider Training Grant from Compass Pathways to Develop Provider Training for COMP360</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/AGMB/agomab-appointments-marino-garcia-naimish-patel</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-11T20:05:10.000Z</news:publication_date>
      <news:title>Agomab Announces Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/IBO/impact-biomedical-reverse-stock-split-merger-zoar-ltd</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-11T20:05:00.000Z</news:publication_date>
      <news:title>Impact BioMedical Inc (NYSE American: IBO) Announces 1 for 12.62 Reverse Stock Split to Pursue Completion of Merger with Zoar Ltd. (previously Dr. Ashley’s Ltd.)</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-canyon-1-trial-data</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-11T20:01:00.000Z</news:publication_date>
      <news:title>Corbus Pharmaceuticals to Host Conference Call to Discuss Topline Data from CANYON-1 Clinical Trial and the Potential of CRB-913 In Obesity</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/PHAR/fda-approves-pharming-joenja-treatment-apds-children</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-11T18:00:00.000Z</news:publication_date>
      <news:title>FDA approves Pharming’s Joenja® as first treatment for children with APDS in the U.S.</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/ACVA/acv-auctions-investigation-copart-sale</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-11T17:00:00.000Z</news:publication_date>
      <news:title>$HAREHOLDER ALERT: The M&amp;A Class Action Firm Announces An Investigation of ACV Auctions Inc. (NYSE: ACVA)</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/AHCO/adapthealth-participate-investor-conferences</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-11T17:00:00.000Z</news:publication_date>
      <news:title>AdaptHealth To Participate in Upcoming Investor Conferences</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/SNY/sanofi-voting-rights-shares-august-2026</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-11T16:30:00.000Z</news:publication_date>
      <news:title>Sanofi: Information concerning the total number of voting rights and shares - August 2026</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/ARAY/accuray-raysearch-collaboration-online-adaptive-therapy</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-11T15:28:00.000Z</news:publication_date>
      <news:title>Accuray and RaySearch Agree to Collaboration Integrating RayStation Software with Accuray Platforms to Accelerate Accuray&apos;s Online Adaptive Capabilities</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/LLY/lilly-acquires-ataibeckley-mental-health-therapies</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-11T13:02:00.000Z</news:publication_date>
      <news:title>Lilly completes acquisition of AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/PHIO/phio-pharmaceuticals-hc-wainwright-conference-2026</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-11T13:00:45.000Z</news:publication_date>
      <news:title>Phio Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/WAT/waters-corporation-jp-morgan-all-stars-conference</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-11T13:00:00.000Z</news:publication_date>
      <news:title>Waters Corporation to Present at the J.P. Morgan U.S. All Stars Conference</news:title>
    </news:news>
  </url>
</urlset>